Business Description
Dimerix Ltd
ISIN : AU000000DXB7
Total Employee Number:
9Description
Dimerix Ltd is a clinical-stage biopharmaceutical company developing drug candidates for inflammatory diseases, including kidney and respiratory diseases, with a focus on new kidney therapies in areas with unmet medical needs. The Company pursues new product concepts and applies scientific knowledge to the discovery of products from early-stage development through to commercialisation. Its products are DMX-652 for Acute Kidney Injury and DMX-200 for Focal Segmental Glomerulosclerosis (FSGS). The Company operates in one segment, being investment in research and development of biopharmaceutical drugs.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 69.63 | |||||
Equity-to-Asset | -0.25 | |||||
Debt-to-Equity | -0.02 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -2.62 | |||||
Beneish M-Score | 4.52 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 4 | |||||
3-Year EPS without NRI Growth Rate | -6 | |||||
3-Year FCF Growth Rate | -30.2 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 32.94 | |||||
9-Day RSI | 42.65 | |||||
14-Day RSI | 48.48 | |||||
3-1 Month Momentum % | 57.14 | |||||
6-1 Month Momentum % | -32.1 | |||||
12-1 Month Momentum % | -40.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.82 | |||||
Quick Ratio | 3.82 | |||||
Cash Ratio | 1.76 | |||||
Days Sales Outstanding | 95.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.7 | |||||
Shareholder Yield % | -0.16 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -854.45 | |||||
Net Margin % | -685.2 | |||||
EBITDA Margin % | -854.45 | |||||
FCF Margin % | -1190.81 | |||||
OCF Margin % | -1190.69 | |||||
ROA % | -41.73 | |||||
ROIC % | -104.64 | |||||
3-Year ROIIC % | -27.84 | |||||
ROC (Joel Greenblatt) % | -26682.06 | |||||
ROCE % | -65.51 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 6.93 | |||||
PS Ratio | 35 | |||||
EV-to-EBIT | -4.17 | |||||
EV-to-EBITDA | -4.17 | |||||
EV-to-Revenue | 35.67 | |||||
EV-to-Forward-Revenue | 4.93 | |||||
EV-to-FCF | -3 | |||||
Earnings Yield (Greenblatt) % | -23.98 | |||||
FCF Yield % | -30.28 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dimerix Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 4.351 | ||
| EPS (TTM) (A$) | -0.05 | ||
| Beta | -0.8183 | ||
| 3-Year Sharpe Ratio | 0.71 | ||
| 3-Year Sortino Ratio | 2.45 | ||
| Volatility % | 60 | ||
| 14-Day RSI | 48.48 | ||
| 14-Day ATR (A$) | 0.015813 | ||
| 20-Day SMA (A$) | 0.29425 | ||
| 12-1 Month Momentum % | -40.86 | ||
| 52-Week Range (A$) | 0.1575 - 0.665 | ||
| Shares Outstanding (Mil) | 600.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dimerix Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dimerix Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| 0.05:1 Stock Split | 2017-10-23 | 0.19 (-9.09%) | ||
| 0.071429:1 Stock Split | 2012-10-04 | 0.22 (+0.00%) | ||
| 0.4:1 Stock Split | 2005-01-24 | 12.06 (+0.00%) | ||
| 5:1 Stock Split | 1992-07-03 | -- |
Show
Entries
Dimerix Ltd Frequently Asked Questions
What is Dimerix Ltd(ASX:DXB)'s stock price today?
The current price of ASX:DXB is A$0.28. The 52 week high of ASX:DXB is A$0.67 and 52 week low is A$0.16.
When is next earnings date of Dimerix Ltd(ASX:DXB)?
The next earnings date of Dimerix Ltd(ASX:DXB) is .
Does Dimerix Ltd(ASX:DXB) pay dividends? If so, how much?
Dimerix Ltd(ASX:DXB) does not pay dividend.
Press Release
Articles on Dimerix Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers